These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival.
    Author: Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhönen S, Kajanti M, Mäntylä M, Tamminen K, Jekunen A, Sarna S, Cantell K.
    Journal: J Interferon Cytokine Res; 1997 Feb; 17(2):103-5. PubMed ID: 9058316.
    Abstract:
    Two hundred thirty-seven patients with small cell lung cancer (SCLC), who had responded to induction chemotherapy and radiotherapy, were randomly assigned to receive low-dose natural interferon-alpha (nIFN alpha) for 6 months; or 6 cycles of maintenance chemotherapy (CAP); or no maintenance therapy (control group). Although there was no difference in median survival between the groups, there was a significant difference (p = 0.04) in the long-term survival of patients with limited disease, in favour of nIFN alpha maintenance therapy. This finding is now confirmed by a further analysis of the most recent data. Ten percent of patients in the IFN group survived for five years or more, but the 5-year-survival rate in the CAP and control groups was only two percent. All long-term survivors had good performance status. The majority had limited disease and had achieved a complete response to the induction therapy. These results suggest that interferon-alpha improves the long-term survival of SCLC patients for whom other prognostic factors are favorable.
    [Abstract] [Full Text] [Related] [New Search]